Our results further demonstrated that KP-metabolites reflect disease severity in PAH patients, with higher levels of KP-metabolites correlating particularly with higher pulmonary vascular resistance, and/or worse NYHA class, and to a lesser extent with reduced cardiac index and shorter 6-min walking distance. Here, NPPA is linked to pulmonary arterial hypertension.